Published in Cancer Res on February 15, 2007
Non-coding RNAs in human disease. Nat Rev Genet (2011) 11.40
miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res (2008) 8.97
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A (2007) 5.20
Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16
MicroRNAs in cancer. Annu Rev Pathol (2009) 4.47
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest (2008) 3.53
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene (2011) 3.02
microRNA involvement in human cancer. Carcinogenesis (2012) 2.98
MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell (2013) 2.92
Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res (2009) 2.58
Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res (2009) 2.43
Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene (2011) 2.42
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem (2011) 1.98
Roles of small RNAs in tumor formation. Trends Mol Med (2010) 1.89
Differential DNA methylation correlates with differential expression of angiogenic factors in human heart failure. PLoS One (2010) 1.89
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer (2009) 1.87
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst (2013) 1.76
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology (2009) 1.76
microRNA 184 regulates expression of NFAT1 in umbilical cord blood CD4+ T cells. Blood (2009) 1.75
Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer (2011) 1.73
Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest (2007) 1.72
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69
CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene (2010) 1.65
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget (2013) 1.64
CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int (2011) 1.62
Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res (2011) 1.60
MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med (2011) 1.59
Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia (2010) 1.58
A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics (2009) 1.56
MicroRNAs, macrocontrol: regulation of miRNA processing. RNA (2010) 1.56
MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis (2012) 1.55
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis (2010) 1.55
microRNA and stem cell function. Cell Tissue Res (2007) 1.54
MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer (2010) 1.51
Causes and consequences of microRNA dysregulation. Cancer J (2012) 1.51
Got target? Computational methods for microRNA target prediction and their extension. Exp Mol Med (2010) 1.49
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA (2009) 1.48
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res (2012) 1.46
miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res (2013) 1.46
Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet (2010) 1.44
Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene (2012) 1.44
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology (2013) 1.41
MicroRNA and colorectal cancer. World J Surg (2009) 1.40
miRNA regulation of cytokine genes. Cytokine (2009) 1.39
DNA methylation of cancer genome. Birth Defects Res C Embryo Today (2009) 1.39
MicroRNAs: molecular features and role in cancer. Front Biosci (Landmark Ed) (2012) 1.32
Advances in microRNAs: implications for immunity and inflammatory diseases. J Cell Mol Med (2009) 1.29
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
Proteins that bind methylated DNA and human cancer: reading the wrong words. Br J Cancer (2008) 1.27
Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics (2010) 1.26
MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis (2010) 1.24
MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS One (2011) 1.23
Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One (2011) 1.22
Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS One (2013) 1.22
Dysregulation of microRNAs in cancer. J Biomed Sci (2012) 1.20
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
Estrogen Regulation of MicroRNA Expression. Curr Genomics (2009) 1.20
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem (2011) 1.19
Epigenetic alteration and microRNA dysregulation in cancer. Front Genet (2013) 1.19
Enjoy the Silence: The Story of let-7 MicroRNA and Cancer. Curr Genomics (2007) 1.19
MicroRNAs in cancer treatment and prognosis. Am J Cancer Res (2012) 1.17
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One (2011) 1.15
Targeted bisulfite sequencing by solution hybrid selection and massively parallel sequencing. Nucleic Acids Res (2011) 1.15
MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One (2011) 1.15
MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One (2013) 1.15
Computational analysis identifies a sponge interaction network between long non-coding RNAs and messenger RNAs in human breast cancer. BMC Syst Biol (2014) 1.14
miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther (2014) 1.13
Epigenetics: connecting environment and genotype to phenotype and disease. J Dent Res (2009) 1.13
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS One (2012) 1.11
Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci (2013) 1.10
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e. J Biol Chem (2011) 1.10
Senescence induction; a possible cancer therapy. Mol Cancer (2009) 1.10
miR-124 suppresses multiple steps of breast cancer metastasis by targeting a cohort of pro-metastatic genes in vitro. Chin J Cancer (2011) 1.09
MicroRNAs and their potential for translation in prostate cancer. Urol Oncol (2009) 1.08
Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer (2013) 1.07
Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One (2013) 1.07
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS One (2010) 1.07
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24
MicroRNA expression in zebrafish embryonic development. Science (2005) 15.52
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Chemical Entities of Biological Interest: an update. Nucleic Acids Res (2009) 8.92
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 5.68
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
A role for RNAi in the selective correction of DNA methylation defects. Science (2009) 4.30
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer (2007) 4.06
Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet (2012) 4.04
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
DNA methylation and cancer. Adv Genet (2010) 3.50
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol (2008) 3.49
Epigenetics and aging: the targets and the marks. Trends Genet (2007) 3.44
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
p300/CBP and cancer. Oncogene (2004) 3.13
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol (2009) 3.05
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology (2008) 2.91
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell (2010) 2.86
MicroRNA biogenesis is required for mouse primordial germ cell development and spermatogenesis. PLoS One (2008) 2.82
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
DNA methylation: a profile of methods and applications. Biotechniques (2002) 2.74
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
The role of histone deacetylases (HDACs) in human cancer. Mol Oncol (2007) 2.72
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping. Cancer Genet Cytogenet (2005) 2.70
The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J (2002) 2.56
Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med (2012) 2.55
Notch signaling is essential for ventricular chamber development. Dev Cell (2007) 2.53
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature (2006) 2.51
Sizing up miRNAs as cancer genes. Nat Med (2005) 2.48
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res (2003) 2.41
Allele-specific histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J (2002) 2.40
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27